Abstract
The neuroleptic malignant syndrome (NMS) is an evidently underdiagnosed but potentially lethal consequence of treatment with potent neuroleptics. The author presents a detailed review of the clinical characteristics and differential diagnosis of the NMS as described in the world literature. Further studies of the incidence, etiology and pathogenesis of the NMS may enhance knowledge of neuroleptic pharmacology and produce more effective means of prevention and treatment.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Antipsychotic Agents / adverse effects*
-
Autonomic Nervous System / drug effects*
-
Cognition Disorders / chemically induced*
-
Consciousness Disorders / chemically induced*
-
Consciousness Disorders / diagnosis
-
Diagnosis, Differential
-
Dose-Response Relationship, Drug
-
Drug Therapy, Combination
-
Haloperidol / adverse effects
-
Humans
-
Malignant Hyperthermia / diagnosis
-
Malignant Hyperthermia / etiology*
-
Muscle Rigidity / chemically induced*
-
Muscle Rigidity / diagnosis
-
Nervous System Diseases / chemically induced*
-
Nervous System Diseases / diagnosis
-
Piperazines / adverse effects
-
Thiothixene / adverse effects
Substances
-
Antipsychotic Agents
-
Piperazines
-
Thiothixene
-
Haloperidol